Target intelligence / Profile preview

R-spondin 2 (RSPO2)

Target: RSPO2
Molecular classification: Secreted protein, Wnt signaling agonist, Ligand for leucine-rich repeat-containing G-protein coupled receptors (GPCRs: LGR4, LGR5, LGR6), Regulator of ubiquitin E3 ligases (ZNRF3, RNF43)

Overview

R-spondin 2 (RSPO2) is a secreted regulatory protein that amplifies Wnt/β-catenin signaling by binding LGR4/5/6 receptors and inhibiting the negative regulators ZNRF3 and RNF43, increasing membrane Wnt receptors and promoting downstream transcription of Wnt target genes. RSPO2 is essential for embryonic development, including limb, craniofacial, and lung morphogenesis, and plays significant roles in stem cell biology and cancer pathogenesis. Aberrant RSPO2 activity, mutations, or gene fusions can drive malignancies, particularly colorectal cancer, and lead to severe developmental syndromes when disrupted. As a master regulator of Wnt signaling with developmental and oncogenic impact, RSPO2 is a focus for diagnostic, prognostic, and therapeutic approaches in oncology and regenerative medicine.

Other names: roof plate-specific spondin-2CRISTIN2TETAMS2HHRRDhRspo2MGC35555RSPO2R-spondin 2 homologUNQ9384/PRO34209

Mechanism of action

Agonism: RSPO2 binds LGR4/5/6, potentiates Wnt/β-catenin signaling by preventing ZNRF3/RNF43-mediated receptor degradation. Antagonism: Inhibitor peptides block RSPO2 function, attenuating Wnt or BMP signaling (RW dendrimer for AML). BMP receptor antagonism: Binding to BMPR1A, impacting BMP signaling.

Biological functions

Activation and amplification of canonical Wnt/β-catenin signalingRegulation of non-canonical Wnt/planar cell polarity signalingCell proliferationStem cell renewalMorphogenesis (including craniofacial and limb development)Cell invasion and migrationRegulation of cancer stem cell properties

Disease associations

Cancer (especially colorectal, hepatocellular, and acute myeloid leukemia)Humerofemoral hypoplasia with radiotibial ray deficiencyTetraamelia syndrome 2 (congenital limb and lung agenesis)Developmental disorders affecting limb, craniofacial, and lung morphogenesis

Safety considerations

Therapeutic challenges: RSPO2 broadly influences stem cell proliferation and organogenesis, so targeting risks off-target effects, disrupted tissue homeostasis, or developmental abnormalitiesCancer risk: Potentiation of Wnt signaling by RSPO2 is linked to oncogenesisDevelopmental toxicity: RSPO2 inactivation results in severe congenital malformations

Interacting drugs

No approved drugs target RSPO2 directly, but inhibitor peptides (e.g., RW dendrimer) have been studied in acute myeloid leukemia (AML)

1 more in the full profile.

Biomarkers

RSPO2 gene expression and fusion status as biomarkers for colorectal cancer prognosis, diagnosis, and therapeuticsRSPO2 mutations and altered expression linked to congenital syndromes and cancer subtypes

Beyond the preview

Go deeper on R-spondin 2 (RSPO2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on R-spondin 2 (RSPO2).

Explore the full profile